Aortoiliac Occlusive Disease

  • Author: Kenneth E McIntyre, Jr, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
 
Updated: Jul 20, 2015
 

Background

In patients with peripheral arterial disease (PAD), obstructing plaques caused by atherosclerotic occlusive disease commonly occur in the infrarenal aorta and iliac arteries. Atherosclerotic plaques may induce symptoms either by obstructing blood flow or by breaking apart and embolizing atherosclerotic and/or thrombotic debris to more distal blood vessels. If the plaques are large enough to impinge on the arterial lumen, reduction of blood flow to the extremities occurs. Several risk factors exist for development of the arterial lesions, and recognition of these factors enables physicians to prescribe nonoperative treatment that may alleviate symptoms as well as prolong life.

Aortoiliac occlusive disease (AIOD) occurs commonly in patients with PAD. Significant lesions in the aortoiliac arterial segment are exposed easily by palpation of the femoral pulses. Any diminution of the palpable femoral pulse indicates that a more proximal obstruction exists. Obstructive lesions may be present in the infrarenal aorta, common iliac, internal iliac (hypogastric), external iliac, or combinations of any or all of these vessels. Occasionally, degenerated nonstenotic atheromatous disease exists in these vessels and may manifest by atheroembolism to the foot, the "blue toe" or "trash foot" syndrome. Generally, patients with aortoiliac PAD have a poorer general prognosis than those with more distal PAD.[1]

Before prosthetic grafts for aortic bypasses became available, the first direct surgical reconstructions on the aorta were performed using the technique of thromboendarterectomy (TEA), first described by Dos Santos of Lisbon in 1947.[2] The initial procedure was performed on a patient with superficial femoral artery (SFA) obstruction, and Dos Santos termed the procedure disobliteration. Wylie adapted this technique to the aortoiliac region and, in 1951, performed the first aortoiliac endarterectomy in the United States.[3] With the discovery of suitable prosthetic graft materials for aortic replacement in the 1960s, surgical treatment of aortoiliac occlusive disease (AIOD) became available to even more patients.

In 1964, Dotter first performed percutaneous iliac angioplasty using a coaxial system of metal dilators.[4] This procedure proved to have limited application, because of the cumbersome nature of the device. However, Dotter's early work paved the way for Grüntzig, who, in 1974, developed a catheter with an inflatable polyvinyl chloride balloon that could be passed over a guidewire.[5] This device became the cornerstone for the percutaneous treatment of arterial occlusive lesions today.

In 1985, Palmaz introduced the first stent that helped to improve the results of angioplasty for arterial occlusive disease.[6] Since the advent of angioplasty and stenting, the technology has evolved at an astronomical rate. The design and quality of endovascular devices, as well as the ease and accuracy of performing the procedures, have improved. These improvements have led to improved patient outcomes following endovascular interventions for AIOD.

Surgical treatment of AIOD has been well standardized for many years, and the outcomes are quite good. However, the additional techniques of percutaneous transluminal angioplasty (PTA) and stenting have offered more alternatives to open surgery and offer successful techniques to patients who may have been considered at an unacceptably high risk for conventional open surgical repairs. Catheter-based endovascular treatments for AIOD offer the advantages of less morbidity, faster recovery, and shorter hospital stays. In fact, most endovascular interventions today are simply performed as outpatient procedures. This chapter reviews the risk factors for development of atherosclerotic occlusive disease of the aorta and iliac arteries and describes the natural history, diagnosis, and treatment of the disease.

For patient education resources, see the Cholesterol Center, as well as High Cholesterol and Cholesterol FAQs.

Next

Pathophysiology

Atherosclerosis is an extraordinarily complex degenerative disease with no known single cause. However, many variables are known to contribute to the development of atherosclerotic lesions. One popular theory emphasizes that atherosclerosis occurs as a response to arterial injury. Factors that are known to be injurious to the arterial wall include mechanical factors such as hypertension and low wall shear stress, as well as chemical factors such as nicotine, hyperlipidemia, hyperglycemia, and homocysteine.

Lipid accumulation begins in the smooth muscle cells and macrophages that occur as an inflammatory response to endothelial injury, and the "fatty streak" begins to form in the arterial wall. The atheroma consists of differing compositions of cholesterol, cholesterol esters, and triglycerides. Some plaques are unstable, and fissures occur on the surface of the plaque that expose the circulating platelets to the inner elements of the atheroma. Platelet aggregation then is stimulated. Platelets bind to fibrin through activation of the glycoprotein (GP) IIb/IIIa receptor on the platelets, and a fresh blood clot forms in the area of plaque breakdown. These unstable plaques are prone to atheromatous embolization and/or propagation of clot that eventually can occlude the arterial lumen.

If the atheroma enlarges enough to occupy at least 50% of the arterial lumen, the flow velocity of blood through that stenosis can significantly increase. The oxygen requirements of the lower extremity at rest are low enough that even with a moderate proximal stenosis, no increase in blood flow velocity occurs. During exercise, however, the oxygen debt that occurs in ischemic muscle cannot be relieved, because of the proximal obstruction of blood flow; this results in claudication symptoms. In more advanced cases, critical tissue ischemia occurs, and neuropathic rest pain or tissue loss ensues. However, critical limb ischemia is seldom, if ever, caused by AIOD alone. Commonly, in patients with critical limb ischemia, multiple arterial segments are involved in the occlusive atherosclerotic process.

Three distinct arterial segments distal to the visceral bearing portion of the abdominal aorta may become diseased by atherosclerosis. Type I atherosclerosis involves the infrarenal aorta and common iliac arteries only. This pattern of atherosclerosis is present in about 5-10% of patients with PAD and occurs more commonly in women. The vessels distal to the common iliac arteries usually are generally normal or only minimally diseased. Type II atherosclerosis involves the infrarenal aorta, common and external iliac arteries, and may extend into the common femoral arteries. This pattern is observed in 35% of patients with PAD. Type III atherosclerosis is the most severe form and, unfortunately, also the most common. This pattern of atherosclerosis involves the infrarenal aorta, iliac, femoral, popliteal, and tibial arteries.

Diabetes mellitus is a risk factor that results in a characteristic pattern of atherosclerotic lesions in patients with PAD. The proximal inflow (aorta, iliac) arteries tend be normal. However, the femoropopliteal segment (including the deep femoral artery), and especially the proximal tibial arteries, are usually severely diseased. Fortunately, the distal tibial and plantar vessels may be normal, enabling successful arterial reconstruction for limb-threatening ischemia.

Previous
Next

Etiology

Atherosclerosis is the most common etiology of occlusive plaques in the aorta and iliac arteries. Several risk factors exist for the development of atherosclerotic plaques in the aortoiliac arterial segment. Cigarette smoking and hypercholesterolemia are observed more commonly in patients with AIOD than in those with infrainguinal occlusive disease. In addition, patients with AIOD tend to be younger and less likely to have diabetes.

An uncommon cause of aortic obstruction is Takayasu disease, a nonspecific arteritis that may cause obstruction of the abdominal aorta and its branches. The etiology of Takayasu disease is not known. For the purposes of this article, only occlusive lesions caused by atherosclerosis are considered.

Previous
Next

Epidemiology

At least 50% of patients with PAD have no symptoms, and therefore, the exact incidence and prevalence of the condition is unknown. However, the incidence of PAD is known to increase with advancing age, so that by age 70 years, as much as 25% of the US population is affected. Occlusive disease involving the aortoiliac arterial segment occurs commonly in patients with PAD and is second only to occlusive disease of the SFA in frequency.

Previous
Next

Prognosis

Outcomes following aortic operations for AIOD are measured in terms of operative mortality and patency of the arterial reconstruction over time. These outcomes are similar for aortoiliac TEA and aortobifemoral bypass (AFB). The operative mortality (30 days) is 2-3%. Long-term patency is excellent too. The patency rate at 5 years after AFB or TEA is 85-90%. If patients continue to smoke, however, these excellent patency rates are reduced by half.

Outcomes for extra-anatomic (axillofemoral or femorofemoral) bypasses are clearly not as good as those for either AFB or aortoiliac TEA. Operative mortality might be expected to be better for extra-anatomic bypass than for AFB because of the extracavitary nature of these procedures and the absence of the requirement for aortic occlusion during the operation. However, the operative mortality (0-4% for femorofemoral bypass and 2-11% for axillobifemoral bypass) is a reflection of the selected patients in whom these procedures are performed. The 5-year primary patency rate with extra-anatomic bypasses performed for AIOD is 19-50% for axillobifemoral bypass and 44-85% for femorofemoral bypass.

Endovascular techniques (ie, PTA and stent placement) offer alternatives to conventional surgical repair. Therefore, understanding the outcomes offered with such interventions is important. Although isolated stenosis of the infrarenal aorta or common iliac artery is uncommon, this lesion is suited ideally to PTA and/or stent placement. With localized, segmental occlusive disease in the aorta, initial technical success can be achieved in 95% of cases, with 5-year patency rates of 80-87% using PTA. Initial success rates with PTA for iliac lesions are 93-97%, with 5-year patency rates of 54-85%. These results seem to be improved when arterial stents are used either primarily or as an adjunct to PTA for the treatment of iliac artery stenosis.

One study investigating the effects of heavy calcification in stent-implanted iliac arteries showed that iliac stents in heavily calcified lesions presented significant residual stenosis; however, even in cases with incomplete expansion of the stent, further blockage was not found, and all stents remained anatomically patent.

In a systematic review and meta-analysis designed to examine the clinical outcomes of endovascular and open bypass treatment for AIOD, Indes et al found that endovascular treatment was associated with shorter hospital stays, lower complication rates, and reduced 30-day mortality, whereas open bypass was associated with higher primary and secondary patency rates at 1, 3, and 5 years.[7]

Previous
 
 
Contributor Information and Disclosures
Author

Kenneth E McIntyre, Jr, MD Professor of Surgery, Chief, Division of Vascular Surgery, University of Nevada School of Medicine; Chief, Surgical Service, Chief, Vascular Surgery, Veterans Administration of Southern Nevada

Kenneth E McIntyre, Jr, MD is a member of the following medical societies: Society for Vascular Surgery, Southern Association for Vascular Surgery, Society for Clinical Vascular Surgery, American College of Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Travis J Phifer, MD 

Travis J Phifer, MD is a member of the following medical societies: American College of Emergency Physicians, American College of Surgeons, American Medical Association, Association for Academic Surgery, Society for Academic Emergency Medicine, Society for Vascular Surgery, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Additional Contributors

Jeffrey Lawrence Kaufman, MD Associate Professor, Department of Surgery, Division of Vascular Surgery, Tufts University School of Medicine

Jeffrey Lawrence Kaufman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society for Artificial Internal Organs, Association for Academic Surgery, Association for Surgical Education, Massachusetts Medical Society, Phi Beta Kappa, Society for Vascular Surgery

Disclosure: Nothing to disclose.

References
  1. Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2. 55(9):898-903. [Medline].

  2. Dos Santos JC. Sur la desobstruction des thrombus arterielles anciennes. Mem Acad Chir. 1947. 73:409.

  3. Wylie EJ. Thromboendarterectomy for arteriosclerotic thrombosis of major arteries. Surgery. 1952. 23:275-292. [Medline].

  4. Dotter C, Judkins M. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and a preliminary report of its application. Circulation. 1964 Nov. 30:654-70. [Medline].

  5. Grüntzig A, Hopff H. [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author's transl)]. Dtsch Med Wochenschr. 1974 Dec 6. 99(49):2502-10, 2511. [Medline].

  6. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology. 1985 Jul. 156(1):73-7. [Medline].

  7. Indes JE, Pfaff MJ, Farrokhyar F, Brown H, Hashim P, Cheung K, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2013 Aug. 20 (4):443-55. [Medline].

  8. [Guideline] Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015 Mar. 61 (3 Suppl):2S-41S. [Medline]. [Full Text].

  9. Weitz JI, Byrne J, Clagett GP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996 Dec 1. 94(11):3026-49. [Medline].

  10. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 Sep 27. 274(12):975-80. [Medline].

  11. Blaisdell FW, Hall AD. Axillary femoral bypass for lower extremity ischemia. Surgery. 1963. 54:563. [Medline].

  12. Iida O, Soga Y, Takahara M, Kawasaki D, Yamauchi Y, Suzuki K, et al. Efficacy of the S.M.A.R.T. Control vs. Other Stents for Aortoiliac Occlusive Disease in Contemporary Clinical Practice. J Endovasc Ther. 2013 May. 20(3):431-9. [Medline].

  13. Goverde PC, Grimme FA, Verbruggen PJ, Reijnen MM. Covered endovascular reconstruction of aortic bifurcation (CERAB) technique: a new approach in treating extensive aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2013 Jun. 54(3):383-7. [Medline].

  14. Szilagyi DE, Smith RF, Elliott JP, et al. Infection in arterial reconstruction with synthetic grafts. Ann Surg. 1972 Sep. 176(3):321-33. [Medline].

  15. TASC Working Group. Endovascular procedures for intermittent claudication. J Vasc Surg. 2000. 31:S97-S112.

  16. Taylor Jr LM, Moneta GL, Porter JM. Natural history and non-operative treatment of chronic lower extremity ischemia. Vasc Surg. 2000. 928-43.

  17. Yeager RA, Moneta GL, Taylor LM Jr, Harris EJ Jr, McConnell DB, Porter JM. Improving survival and limb salvage in patients with aortic graft infection. Am J Surg. 1990 May. 159 (5):466-9. [Medline].

  18. Baker JD. Physiologic studies to document severity of aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St Louis, MO: Mosby-Year Book; 2001.

  19. Ballard JL, Bergan JJ, Singh P, et al. Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. J Vasc Surg. 1998 Jul. 28(1):94-101; discussion 101-3. [Medline].

  20. Ballard JL, Sparks SR, Taylor FC, et al. Complications of iliac artery stent deployment. J Vasc Surg. 1996 Oct. 24(4):545-53; discussion 553-5. [Medline].

  21. Barbera L, Mumme A, Metin S, et al. Operative results and outcome of twenty-four totally laparoscopic vascular procedures for aortoiliac occlusive disease. J Vasc Surg. 1998 Jul. 28(1):136-42. [Medline].

  22. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997 Jul. 204(1):87-96. [Medline].

  23. Brewster DC. Current controversies in the management of aortoiliac occlusive disease. J Vasc Surg. 1997 Feb. 25(2):365-79. [Medline].

  24. Brewster DC, Darling RC. Optimal methods of aortoiliac reconstruction. Surgery. 1978 Dec. 84(6):739-48. [Medline].

  25. Cambria RP, Brewster DC, Abbott WM, et al. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. J Vasc Surg. 1990 Feb. 11(2):314-24; discussion 324-5. [Medline].

  26. Chang IS, Park KB, Do YS, Park HS, Shin SW, Cho SK, et al. Heavily calcified occlusive lesions of the iliac artery: long-term patency and CT findings after stent placement. J Vasc Interv Radiol. 2011 Aug. 22 (8):1131-7.e1. [Medline].

  27. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8. 308 (6921):81-106. [Medline]. [Full Text].

  28. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985 Mar. 71(3):510-5. [Medline].

  29. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 6. 326(6):381-6. [Medline].

  30. DeBakey ME, Cooley DA, Crawford ES, Morris GC Jr. Clinical application of a new flexible knitted Dacron arterial substitute. 1958. Am Surg. 2008 May. 74 (5):381-6. [Medline].

  31. Donaldson MC, Louras JC, Bucknam CA. Axillofemoral bypass: a tool with a limited role. J Vasc Surg. 1986 May. 3(5):757-63. [Medline].

  32. el-Massry S, Saad E, Sauvage LR, et al. Axillofemoral bypass with externally supported, knitted Dacron grafts: a follow-up through twelve years. J Vasc Surg. 1993 Jan. 17(1):107-14; discussion 114-5. [Medline].

  33. Ernst E, Fialka V. A review of the clinical effectiveness of exercise therapy for intermittent claudication. Arch Intern Med. 1993 Oct 25. 153(20):2357-60. [Medline].

  34. Funovics MA, Lackner B, Cejna M, et al. Predictors of long-term results after treatment of iliac artery obliteration by transluminal angioplasty and stent deployment. Cardiovasc Intervent Radiol. 2002 Sep-Oct. 25(5):397-402.

  35. Harrington ME, Harrington EB, Haimov M, et al. Iliofemoral versus femorofemoral bypass: the case for an individualized approach. J Vasc Surg. 1992 Dec. 16(6):841-52; discussion 852-4. [Medline].

  36. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995 Mar 1. 91(5):1472-9. [Medline].

  37. Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II. J Vasc Surg. 2011 Apr. 53(4):992-9. [Medline].

  38. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 2001 Jan. 119(1 Suppl):283S-299S. [Medline].

  39. Lee GC, Yang SS, Park KM, Park Y, Kim YW, Park KB, et al. Ten year outcomes after bypass surgery in aortoiliac occlusive disease. J Korean Surg Soc. 2012 Jun. 82(6):365-9. [Medline]. [Full Text].

  40. Legemate DA, Teeuwen C, Hoeneveld H, et al. Value of duplex scanning compared with angiography and pressure measurement in the assessment of aortoiliac arterial lesions. Br J Surg. 1991 Aug. 78(8):1003-8. [Medline].

  41. Malone JM, Moore WS, Goldstone J. The natural history of bilateral aortofemoral bypass grafts for ischemia of the lower extremities. Arch Surg. 1975 Nov. 110(11):1300-6. [Medline].

  42. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991 Apr. 87(2-3):119-28. [Medline].

  43. Messina LM. Endarterectomy for atherosclerotic aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St Louis, MO: Mosby-Year Book; 2001. 381-4.

  44. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993 Sep. 88(3):837-45. [Medline].

  45. Passman MA, Taylor LM, Moneta GL, et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 1996 Feb. 23(2):263-9; discussion 269-71. [Medline].

  46. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio. Circulation. 1994 Jan. 89(1):511-31. [Medline].

  47. Prendiville EJ, Burke PE, Colgan MP, et al. The profunda femoris: a durable outflow vessel in aortofemoral surgery. J Vasc Surg. 1992 Jul. 16(1):23-9. [Medline].

  48. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996 Jan. 23(1):104-15. [Medline].

  49. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20. 314(8):488-500. [Medline].

  50. Said S, Mall J, Peter F, Muller JM. Laparoscopic aortofemoral bypass grafting: human cadaveric and initial clinical experiences. J Vasc Surg. 1999 Apr. 29(4):639-48. [Medline].

  51. Schafer AL. Antiplatelet therapy. Am J Med. 1996 Aug. 101(2):199-209. [Medline].

  52. Schmalstieg J, Zeller T, Tübler T, Sixt S, Schwencke C, Sandstede J, et al. Long term data of endovascularly treated patients with severe and complex aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2012 Jun. 53(3):291-300. [Medline].

  53. Schneider PA. Endovascular or open surgery for aortoiliac occlusive disease?. Cardiovasc Surg. 2002 Aug. 10(4):378-82. [Medline].

  54. Sharp WJ, Hoballah JJ, Mohan CR, et al. The management of the infected aortic prosthesis: a current decade of experience. J Vasc Surg. 1994 May. 19(5):844-50. [Medline].

  55. Stoney RJ, Reilly LM. Endarterectomy for aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. St Louis, MO: Mosby-Year Book; 1987. 157.

  56. Szilagyi DE, Elliott JP, Smith RF. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg. 1986 Mar. 3(3):421-36. [Medline].

 
Previous
Next
 
Type I atherosclerosis with occlusive disease limited to the infrarenal aorta and common iliac arteries.
Large collateral vessels confirm hemodynamic significance of left common iliac stenosis.
Successful treatment of focal high-grade left common iliac stenosis with Palmaz stent.
 
Medscape Consult
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.